111 Views

Sentien grabs Series A funds from BIVF and Portage Biotech

Medford, Massachusetts-based Sentien Biotechnologies Inc, which develops cell-based therapies for acute organ failure, has raised an undisclosed amount of Series A funding. The investors were Boehringer Ingelheim Venture Fund USA Inc and Portage Biotech Inc. In addition to the funding, Dr. Martin Heidecker, a managing director at BIVF and Dr. Greg Bailey, chairman of Portage, have been added to Sentien’s board of directors.

ViraTherapeutics raises $4 mln

ViraTherapeutics GmbH said Wednesday it raised 3.6 million euros (US$4 million) in a first close of a Series A financing round. Boehringer Ingelheim Venture Fund and EMBL Ventures co-led the round, while Austria Wirtschaftsservice through its Venture-Capital-Initiative also invested. Innsbruck, Austria-based ViraTherapeutics is biopharmaceutical company developing cancer immunotherapies.

Promethera Biosciences nabs $31.4 Series C

Belgium-based Promethera Biosciences, a biotech firm that focuses on treating liver diseases, has closed its Series C round at $31.4 million. The investors included SFPI-FPIM, Vesalius Biocapital, Boehringer Ingelheim Venture Fund and SMS Investments.

Rigontec raises $11.95 mln

Rigontec GmbH said Tuesday it raised €9.45 million (US$11.95 million) in a first close of a Series A round co-led by Wellington Partners and Boehringer Ingelheim Venture Fund. Other investors include NRW Bank and High-Tech Gründerfonds. Rigontec, a biopharmaceutical company, is developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.

Eyevensys Receives Investment From Boehringer Ingelheim

Eyevensys said it received an equity investment from the Boehringer Ingelheim Venture Fund. Further details were not available. The company raised about $2.1 million in its first round of funding in January 2012. It said early investors – Innobio, managed by CDC Entreprises; Inserm Transfert Initiative; and CapDecisif Management – plan to participate in the second round.

ArmaGen Technologies Raises $17m Series A

ArmaGen Technologies has closed a $17 million Series A financing to support the development of brain-penetrating recombinant protein therapeutics. The lead investor is Boehringer Ingelheim Venture Fund, joined by Shire plc, Takeda Ventures, Inc., and Mitsui & Co. Global Investment, Inc.

PE HUB Community

Join the 12523 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget